Log In
Print
BCIQ
Print
Print this Print this
 

ALLN-177

  Manage Alerts
Collapse Summary General Information
Company Allena Pharmaceuticals Inc.
DescriptionOral recombinant oxalate degrading enzyme
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationHyperoxaluria
Indication DetailsTreat hyperoxaluria; Treat secondary hyperoxaluria
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today